Trials / Completed

CompletedNCT04162795

A Study to Evaluate Cooling Sensation of an Allergy Product in Adults With a History of Allergies

An Open Label, Multi-center Study to Evaluate Sensory Attributes of an Antihistamine Product

Status: Completed
Phase: Phase 4
Study type: Interventional
Enrollment: 468 (actual)

Sponsor: Bayer · Industry
Sex: All
Age: 18 Years – 65 Years
Healthy volunteers: Not accepted

Summary

In this study, researchers were primarily interested in evaluating the level of agreement of cooling sensation provided by this chewable, flavored, allergy medicine. Participants joining this study received one test drug tablet and were asked to chew completely before swallowing the drug. A questionnaire was used to collect the feedback from participants. The study involved only one (1) visit and participant stayed in this study for about 60-75 minutes to evaluate the cooling sensation as well as other sensory attributes perceived in the mouth, nose and throat.

Conditions

Allergic Rhinitis

Interventions

Type	Name	Description
DRUG	Loratadine (Claritin, BAY76-2211)	Chewable tablet, oral, single dose

Timeline

Start date: 2019-11-12
Primary completion: 2019-11-13
Completion: 2019-11-13
First posted: 2019-11-14
Last updated: 2021-02-04
Results posted: 2021-02-04

Locations

1 site across 1 country: United States

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT04162795. Inclusion in this directory is not an endorsement.